Proprotein convertase subtilisin/kexin type 9 (PCSK9), for example, has developed into a novel therapeutic target for hypercholesterolemia and related cardiovascular illnesses, as well as a crucial enzyme in lipid metabolism. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.